氯胺酮/丙泊酚混合液与依托咪酯用于危重症患者插管:KEEP PACE随机临床试验
本研究为在三级学术医疗中心开展的分层(休克状态和单元类型)、多单元、随机、平行组优效性临床试验,纳入成人内科/外科及移植/肿瘤ICU需紧急插管的危重症患者,随机接受氯胺酮/丙泊酚混合液(各0.5 mg/kg)或减量依托咪酯(0.15 mg/kg)。主要终点为给药后5分钟平均动脉压较基线的变化,结果显示两组无统计学显著差异(治疗差异-2.1 mmHg,95%CI -6.9至+2.7 mmHg,p=0.385)。依托咪酯组更多患者需要非红细胞输血(16例[22%] vs 8例[10%],p=0.046),在行肾上腺功能检测的患者中,依托咪酯组更多出现即刻肾上腺功能不全(13/16[81%] vs 5/13[38%],p=0.027)。作者认为,在异质性危重症人群中,氯胺酮/丙泊酚混合液不优于减量依托咪酯维持插管期血流动力学,但似乎是安全的替代诱导剂。
要点
- 在危重症患者紧急插管中,氯胺酮/丙泊酚混合液(各0.5 mg/kg)与减量依托咪酯(0.15 mg/kg)在给药后5分钟平均动脉压变化上无统计学显著差异(治疗差异-2.1 mmHg,95%CI -6.9至+2.7 mmHg,p=0.385)。
- 给药后10分钟和15分钟平均动脉压变化、新发血管活性药物使用或插管困难程度两组均无统计学显著差异。
- 依托咪酯组需要非红细胞输血的患者更多(16例[22%] vs 8例[10%],p=0.046)。
- 在行肾上腺功能检测的患者中,依托咪酯组即刻肾上腺功能不全的发生率更高(13/16[81%] vs 5/13[38%],p=0.027)。
- 严重不良事件罕见:氯胺酮/丙泊酚混合液组2例(3%)(心脏骤停、低血压),依托咪酯组4例(5%)(高血压、低血压)(p=0.430)。
适用人群与场景
- 成人内科/外科及移植/肿瘤ICU需紧急插管的危重症患者。
处置流程与药物剂量
- 氯胺酮/丙泊酚混合液:氯胺酮0.5 mg/kg和丙泊酚0.5 mg/kg,用于危重症患者紧急插管诱导。
- 减量依托咪酯:0.15 mg/kg,用于危重症患者紧急插管诱导。
研究设计与关键结果
- 研究类型:分层(休克状态和单元类型)、多单元、随机、平行组优效性临床试验,在三级学术医疗中心开展。
- 样本量:160例随机,152例纳入意向性治疗分析(氯胺酮/丙泊酚混合液组79例,依托咪酯组73例)。
- 主要终点:给药后5分钟平均动脉压较基线变化,治疗差异(氯胺酮/丙泊酚混合液-依托咪酯)-2.1 mmHg,95%CI -6.9至+2.7 mmHg,p=0.385,无统计学显著差异。
- 次要终点:给药后10分钟和15分钟平均动脉压变化、新发血管活性药物使用、插管困难程度两组均无统计学显著差异。
- 不良事件:依托咪酯组更多患者需要非红细胞输血(16例[22%] vs 8例[10%],p=0.046);在行肾上腺功能检测的患者中,依托咪酯组更多出现即刻肾上腺功能不全(13/16[81%] vs 5/13[38%],p=0.027);严重不良事件氯胺酮/丙泊酚混合液组2例(3%)(心脏骤停、低血压),依托咪酯组4例(5%)(高血压、低血压)(p=0.430)。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT),证据等级:治疗/护理管理,II级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在异质性危重症人群中,氯胺酮/丙泊酚混合液在维持插管期血流动力学方面不优于减量依托咪酯,但作者认为其似乎是安全的替代诱导剂。
指南或共识出处
- KEEP PACE随机临床试验(ClinicalTrials.gov NCT02105415)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Periintubation hypotension is associated with poor outcomes in the critically ill. We aimed to determine if an admixture of ketamine and propofol for emergent endotracheal intubation in critically ill patients was superior to etomidate. Primary endpoint was the change in mean arterial pressure from baseline to 5 minutes postdrug administration.
METHODS: Emergent-use, stratified (shock status and unit type), multiunit, randomized, parallel-group superiority clinical trial was conducted at a tertiary academic medical center. Adult medical/surgical and transplant/oncologic intensive care unit patients undergoing emergent intubation were assigned randomly to receive either ketamine/propofol admixture (0.5 mg/kg of ketamine and propofol each) or reduced dose etomidate (0.15 mg/kg) for emergent intubation.
RESULTS: One hundred sixty participants were randomized, and 152 (79 ketamine/propofol admixture, 73 etomidate) were included in the intention-to-treat analysis. There was no statistically significant difference in mean arterial pressure change from baseline to 5 minutes postdrug administration (treatment difference [ketamine/propofol admixture-etomidate]: -2.1 mm Hg; 95% confidence interval, -6.9 mm Hg to +2.7 mm Hg; p = 0.385). In addition, no statistically significant difference was demonstrated in the change of mean arterial pressure from baseline at 10 minutes and 15 minutes postdrug administration, no statistical difference in the use of new-onset vasoactive agents or difficulty of intubation between groups. More patients in the etomidate group required non-red blood cell transfusions (16 [22%] vs. 8 [10%], p = 0.046). For patients who had adrenal testing performed, more patients in the etomidate group developed immediate adrenal insufficiency (13 [81%] of 16 vs. 5 [38%] of 13, p = 0.027). Serious adverse events were rare, 2 (3%) (cardiac arrest, hypotension) in ketamine/propofol admixture and 4 (5%) (hypertension, hypotension) in etomidate (p = 0.430).
CONCLUSION: In a heterogeneous critically ill population, ketamine/propofol admixture was not superior to a reduced dose of etomidate at preserving per-intubation hemodynamics and appears to be a safe alternative induction agent in the critically ill.
LEVEL OF EVIDENCE: Therapeutic/Care Management, level II.
TRIAL REGISTRY: ClinicalTrials.gov, NCT02105415, Ketamine/Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial, IRB 13-000506, Trial Registration: March 31, 2014.
参考来源
- Smischney NJ, Nicholson WT, Brown DR, et al. Ketamine/propofol admixture vs etomidate for intubation in the critically ill: KEEP PACE Randomized clinical trial. J Trauma Acute Care Surg. 2019. PMID: 31335755. doi:10.1097/TA.0000000000002448
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。